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Introduction
Maternal smoking during pregnancy increases the risk of several 
adverse birth outcomes including stillbirth. A meta-analysis of four 
studies from Australia, Sweden, Canada, and the United States 
found maternal smoking to increase the risk of stillbirth by 36%.1 
Despite this, 12% of pregnant women in the United Kingdom,2 
13% in the United States,3 and 15% in Australia4 still smoke dur-
ing pregnancy. Therefore, reducing smoking during pregnancy is a 
global public health priority. Pharmacotherapy, specifically the use 
of nicotine replacement therapy (NRT) is being adopted in several 
national guidelines for supporting pregnant smokers to quit, based 
on the notion that NRT is probably safer than smoking.5–7 In the 
United Kingdom, approximately 11% of pregnant smokers are pre-
scribed NRT in primary care,8 despite a lack of evidence concerning 
its safety in pregnancy.9 Evidence specifically in relation to stillbirth 
is limited to one population-based study using the Danish National 
Birth Cohort (DNBC) which found no increased risk of stillbirth 
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Abstract
Introduction: We aimed to compare risk of stillbirth between maternal smokers and those pre-
scribed nicotine replacement therapy (NRT) during pregnancy.
Aims and Methods: We conducted a cross-sectional analysis on a pregnancy cohort of 220,630 
singleton pregnancies ending in live or stillbirth between 2001 and 2012 from The Health 
Improvement Network UK general practice database. Women were categorized into three groups: 
NRT (prescribed during pregnancy or 1 month before conception); smokers; and controls (non-
smokers without a pregnancy NRT prescription). We calculated Odds ratios (OR) and correspond-
ing 95% confidence intervals (CI) for stillbirth in the NRT group and smokers compared to controls.
Results: A total of 805 pregnancies ended in stillbirth (3.6/1000 births). Absolute risks of stillbirth 
in NRT and smoker groups were both 5/1000 births compared with 3.5/1000 births in the control 
group. Compared with the control group, the adjusted odds of stillbirth in the NRT group was not 
statistically significant (OR = 1.35, 95% CI 0.91 to 2.00), although it was similar in magnitude to that 
in the smokers group (OR = 1.41, 95% CI 1.13 to 1.77).
Conclusions: We found no evidence of a statistically significant association between being pre-
scribed NRT during pregnancy and odds of stillbirth compared with nonsmoking women. Although 
our study had much larger numbers than any previously, an even larger study with biochem-
ically validated smoking outcome data and close monitoring of NRT use throughout pregnancy is 
required to exclude effects on findings of potential exposure misclassification.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloaded from https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/nty019/4831224
by Periodicals Department user
on 27 March 2018
Nicotine & Tobacco Research, 2018, Vol. 00, No. 002
associated with NRT use in the first 27 weeks of pregnancy (haz-
ard ratio [HR] = 0.57, 95% confidence interval [CI] 0.28 to 1.16 
compared with those who did not use NRT and did not smoke). 
Information on NRT use and smoking status in the DNBC was 
ascertained up to the time of interview, at approximately 17 weeks 
of gestation, so it is possible that women’s exposure status may have 
changed during the second or third trimesters. A meta-analysis of 
four randomized controlled trials assessing stillbirth as a secondary 
outcome reported a raised but not significant pooled risk ratio of 
1.24 (95% CI 0.54 to 2.84) for NRT use compared with placebo.10 
However, randomized controlled trials assessing effectiveness of 
NRT patches and gum for quitting do not provide such safety evi-
dence as they have inadequate power to assess rare outcomes.11–13
In light of limited safety evidence, in its recent international 
guidelines on prevention and management of tobacco use in preg-
nancy, the World Health Organization (WHO) recognized an urgent 
need for more research into the effects of NRT on pregnant women 
and the fetus, along with its efficacy.14 Therefore, using a large pop-
ulation-based pregnancy cohort, we investigated whether NRT pre-
scribed in UK primary care is associated with stillbirth, compared 
with pregnant women recorded as smokers not prescribed NRT and 
a nonsmoker control group.
Methods
Data Source and Study Population
The Health Improvement Network (THIN) is a UK database of 
anonymized electronic primary care records, including sociodemo-
graphic information, diagnoses, prescriptions, and investigations. 
The validity of recorded diagnoses and prescriptions is high,15 and 
THIN has been previously validated for its recorded population 
prevalence of smoking at a national level for both the general popu-
lation16 and pregnant women.17 Furthermore, fertility rates in THIN 
are highly comparable to national fertility rates.18 At the time of this 
study, THIN contained longitudinal prospectively collected data 
from 570 general practices across the United Kingdom, covering 6% 
of the UK population.19 We created our study population extracting 
all the singleton pregnancies with deliveries between 2000 and 2013.
Exposure
All pregnant women with a recorded prescription for NRT dur-
ing pregnancy in their primary care records were identified, using 
Multilex drug codes for all formulations available in the United 
Kingdom according to the British National Formulary (BNF),20 and 
classified as the NRT group, provided they did not have a current 
smoking Read code following the NRT prescription. Women with 
a prescription for NRT in the 4 weeks before conception were also 
included in the NRT group because it is likely that the medication 
could have been consumed during the early stages of pregnancy. 
Smoking status during pregnancy was determined from a previously 
validated algorithm using smoking status Read codes.16,17 Using 
this algorithm, we categorized women as smokers (those recorded 
as smokers at any point from conception until delivery) or controls 
(those exclusively recorded as nonsmokers at any point from con-
ception until delivery). In 2004, the introduction of the Quality and 
Outcomes Framework (QOF) brought several pay-for-performance 
targets to primary care, including the electronic recording of smok-
ing and smoking cessation advice. Since these data are recorded in 
routine primary care where repeat recordings for ex- and never-
smokers are not required in certain scenarios, use of these QOF rules 
further facilitated identification of controls.21 Firstly, if there was no 
smoking status record during pregnancy, but women were recorded 
as never-smokers at any time during their active registration period 
when they were over 25 years of age, they were included in the con-
trol group. Secondly, if a woman did not have a smoking status rec-
ord during pregnancy but was recorded as an ex-smoker for three 
consecutive years before pregnancy, we categorized her as an ex-
smoker and she was thus included in the control group. After consid-
ering these QOF rules, all remaining women with missing smoking 
status were excluded from the study. More details on this approach 
of defining nonsmoking controls have been previously published.9
Outcome
Stillbirth was defined as a baby born with no signs of life at or after 
28 weeks of gestation, in accordance with the WHO definition.22 
Information on the following potential confounders was also extracted 
due to known associations between these factors/conditions or their 
treatments and both stillbirth and maternal smoking:23–31 women’s age 
at conception; socioeconomic deprivation (quintile of the Townsend 
Index of deprivation);32 pre-pregnancy body mass index; and recorded 
diagnoses of medical conditions before or during pregnancy (hyperten-
sion, epilepsy, diabetes, asthma, and mental illness including depres-
sion, anxiety, bipolar disorder, schizophrenia, and other psychoses). All 
code lists are available from the authors on request.
Statistical Analysis
The absolute risk of stillbirth was calculated as the total number of 
stillbirths divided by the number of stillbirths and live births com-
bined. This was estimated for the entire population as well as each 
exposure group (ie, NRT group, smokers, and controls). We used 
logistic regression to compute odds ratios (OR) and corresponding 
95% CIs for stillbirth for the NRT group and smokers, compared 
with the control group. All potential confounders that had a stat-
istically significant association (p < .05) with the exposure and the 
outcome in chi-squared tests were included in the final model. Some 
women in the study period had more than one pregnancy, and there-
fore, we used generalized estimating equations with an exchange-
able correlation structure to take potential correlation between 
pregnancies into account.33 The reference group was then changed 
to smokers, and the ORs and corresponding 95% CIs were recal-
culated. All analysis was conducted in Stata MP 12 (Stata Corp., 
College Station, TX).
Results
Baseline Characteristics
The study population included 220 630 singleton pregnancies deliv-
ered from 2001 to 2012, of which 805 ended in stillbirth, a preva-
lence of 3.6/1000 births. Table 1 presents the baseline characteristics 
of mothers overall and by birth outcome. Pregnancies that were con-
ceived at later maternal ages (≥35 years) resulted in a higher preva-
lence of stillbirth. Diabetes was also more common in pregnancies that 
ended in stillbirth compared with live births (5.0% vs. 3.2%). The dis-
tribution of socioeconomic status and the prevalence of other chronic 
illnesses like asthma, hypertension, and mental illness were compar-
able in women with stillbirth and those with live births. For women 
with an NRT prescription, the average duration of NRT prescription 
was 2 weeks (interquartile range: 6 days to 2weeks), and 80% of NRT 
prescriptions were recorded within the first two trimesters.
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Table 2 presents the characteristics of mothers according to each 
exposure group. Mothers in the smoking and NRT group were con-
siderably younger compared with the control group. About half of 
the mothers in the NRT and smoking group belonged to the two 
most deprived quintiles compared with about a quarter in the con-
trol group. In addition, there was a higher proportion of mothers in 
the NRT and smoking groups with mental illness compared with the 
control group (20.0%, 16.0%, and 7.8%, respectively).
Absolute and Relative Risks of Stillbirth
Table 3 presents the absolute and relative risks of stillbirth by each 
exposure group. The absolute risk of stillbirth in the NRT group 
and amongst smokers was 5/1000 births, compared with 3.5/1000 
births in the control group. In the unadjusted analysis, NRT was 
associated with a 44% increase in the odds of stillbirth compared 
with the reference group that was not statistically significant (OR 
1.47, 95% CI 0.97 to 2.14) while smoking was associated with 
a statistically significant 52% increase in the risk of stillbirth 
(OR 1.52, 95% CI 1.23 to 1.89). After adjusting for potential 
confounders including maternal age, socioeconomic status, pre-
pregnancy body mass index, and diabetes, there was still no stat-
istically significant increase in the risk of stillbirth in the NRT 
group in comparison with the control group (OR 1.35, 95% CI 
0.91 to 2.00); however, smoking during pregnancy was still asso-
ciated with a 41% statistically significant increased risk of still-
birth (OR 1.41, 95% CI 1.13 to 1.77). When the reference group 
was changed to smokers, there was still no statistically significant 
association between NRT and stillbirth (OR 0.95, 95% CI 0.62 
to 1.48).
Discussion
Main Findings
Using 220 630 singleton pregnancies, we found that the absolute risk 
of stillbirth was very similar between the NRT and smoker groups. 
Although the effect estimates for both NRT and smoking were very 
similar, we found no statistically significant association between 
NRT being prescribed during pregnancy and stillbirth. Women who 
smoked during pregnancy had a 41% increased risk of stillbirth 
compared with the control group, which included never-smokers 
and ex-smokers.
Strengths and Limitations
This is the largest study to date to investigate the association 
between NRT prescribing in pregnant women and stillbirth. 
However, because of the low prescribing of NRT in pregnancy,8 an 
even larger sample size is required to assess the association with 
adequate power. Stillborn babies are usually not registered in pri-
mary care. Therefore, the ascertainment of stillbirth in this study is 
based on the documentation of such events in maternal primary care 
records. Approximately 97% of deliveries in England and Wales in 
2011 took place in NHS hospitals, maternity units, and maternity 
wings,34 and all the delivery information recorded in inpatient data 
should, but may not always, be transferred into primary care records. 
Table 1. Baseline Characteristics of the Study Population by Outcome
All pregnancies  
(N = 220 630)
Pregnancies ending in 
live birth  
(N = 219 825)
Pregnancies 
ending in stillbirth 
(N = 805)
p valuen % n % n %
Age at conception
 15–19 years 9731 4.4 9684 4.4 47 5.8 <.001
 20–24 years 32 585 14.8 32 453 14.8 132 16.4
 25–29 years 58 649 26.6 58 459 26.6 190 23.6
 30–34 years 70 605 32.0 70 393 32.0 212 26.3
 35–39 years 40 210 18.2 40 043 18.2 167 20.7
 40–44 years 8406 3.8 8352 3.8 54 6.7
 45–49 years 444 0.2 441 0.2 3 0.4
Townsend score in quintiles
 Quintile 1 (least deprived) 48 205 21.8 48 071 21.9 134 16.6 .001
 Quintile 2 41 210 18.7 41 064 18.7 146 18.1
 Quintile 3 43 584 19.8 43 411 19.7 173 21.5
 Quintile 4 40 455 18.3 40 300 18.3 155 19.3
 Quintile 5 (most deprived) 29 431 13.3 29 294 13.3 137 17.0
 Missing 17,745 8.0 17,685 8.0 60 7.5
Preconception body mass index (kg/m2)
 Normal (18.5–24.9) 81 408 36.9 81 157 36.9 251 31.2 .001
 Underweight (<18.5) 5445 2.5 5424 2.5 21 2.6
 Overweight (25–29.9) 39 959 18.1 39 796 18.1 163 20.2
 Obese (≥30) 28 308 12.8 28 174 12.8 134 16.6
 Missing 65 510 29.7 65 274 29.7 236 29.3
Asthma 22 444 10.2 22 368 10.2 76 9.4 .491
Hypertension 6502 2.9 6472 2.9 30 3.7 .190
Diabetes 7076 3.2 7036 3.2 40 5.0 .004
Mental illness 19 344 8.8 19 273 8.8 71 8.8 .958
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Therefore, we may have missed cases of stillbirth. Nevertheless, the 
prevalence of stillbirth in this study was 3.6/1000 live and stillbirths, 
which is comparable to the national prevalence of 5.2/1000 births in 
the United Kingdom.35 This slightly lower rate of stillbirth in THIN 
compared with the national prevalence may be attributed to the 
slight under-representation of general practices from more socioeco-
nomically deprived areas in THIN. The effects of smoking or NRT 
use during pregnancy on stillbirth may be mediated by outcomes 
such as congenital anomalies;36 however, comprehensive data on 
congenital anomalies in these stillbirths are not available as a very 
small proportion of congenital anomalies are diagnosed antenatally 
and it is not routine conduct a full autopsy after stillbirth for a full 
diagnosis of congenital anomalies. Furthermore, in our earlier work, 
we found no statistically significant increased risk for major congeni-
tal anomalies associated with NRT use.9
We used primary care records to ascertain NRT exposure which 
is a more objective measurement of drug prescribing and use during 
pregnancy than self-reports by mothers in other studies.37,38 We rec-
ognize, however, the inherent inaccuracy in ascertaining true drug 
exposure in observational studies. In the United Kingdom, pregnant 
women can access NRT in settings other than the GP practice, such 
as through NHS Stop Smoking Services for Pregnancy (SSSP), over-
the-counter purchases in pharmacies, and off-the-shelf purchases in 
supermarkets. However, only 3% of pregnant women access an SSSP 
on average each year,39,40 and a survey of all SSSPs in England con-
ducted between April 2010 and March 2011 reported that almost 
half of the NRT provided by these services was issued through GPs.41 
Furthermore, the prevalence of medication use without prior con-
sultation with a health professional is lower during pregnancy than 
when women are not pregnant;42 NRT packaging clearly instructs 
pregnant women to consult a doctor before using these, and in the 
Table 2.  Baseline Characteristics of the Study Population by Exposure Status
All pregnancies  
(N = 220 630)
Control group  
(N = 197 002)
Smokers  
(N = 18 407)
NRT group  
(N = 5221)
p valuen % n % n % n %
Age at conception
 15–19 years 9731 4.4 6890 3.5 2384 13.0 457 8.8 <.001
 20–24 years 32 585 14.8 26 095 13.2 5211 28.3 1279 24.5
 25–29 years 58 649 26.6 52 440 26.6 4755 25.8 1454 27.8
 30–34 years 70 605 32.0 65 794 33.4 3636 19.8 1175 22.5
 35–39 years 40 210 18.2 37 582 19.1 1931 10.5 697 13.3
 40–44 years 8406 3.8 7797 4.0 456 2.5 153 2.9
 45–49 years 444 0.2 404 0.2 34 0.2 6 0.1
Townsend score in quintiles
 Quintile 1 (least deprived) 48 205 21.8 45 900 23.3 1792 9.7 513 9.8 <.001
 Quintile 2 41 210 18.7 38 369 19.5 2195 11.9 646 12.4
 Quintile 3 43 584 19.8 39 024 19.8 3541 19.2 1019 19.5
 Quintile 4 40 455 18.3 34 236 17.4 4805 26.1 1414 27.1
 Quintile 5 (most deprived) 29 431 13.3 23 348 11.9 4816 26.2 1267 24.3
 Missing 17 745 8.0 16 125 8.2 1258 6.8 362 6.9
Preconception body mass index (kg/m2)
 Normal (18.5–24.9) 81 408 36.9 74 752 37.9 5101 27.7 1555 29.8 <.001
 Underweight (<18.5) 5445 2.5 4681 2.4 606 3.3 158 3.0
 Overweight (25–29.9) 39 959 18.1 36 446 18.5 2662 14.5 851 16.3
 Obese (≥30) 28 308 12.8 25 444 12.9 2214 12.0 650 12.4
 Missing 65 510 29.7 55 679 28.3 7824 42.5 2007 38.4
Asthma 22 444 10.2 19 565 9.9 2227 12.1 652 12.5 <.001
Hypertension 6502 2.9 6028 3.1 368 2.0 106 2.0 <.001
Diabetes 7076 3.2 6518 3.3 418 2.3 140 2.7 <.001
Mental illness 19 344 8.8 15 350 7.8 2952 16.0 1042 20.0 <.001
NRT = nicotine replacement therapy.
Table 3. Absolute and Relative Risks of Stillbirth for NRT and Smoking Groups Compared With Controls
Absolute risk of 
stillbirth
 Unadjusted OR (95% CI) p value Adjusted OR (95% CI)a p valuen %
Control group 683 0.35 Reference Reference
NRT group 26 0.50 1.44 (0.97 to 2.14) .069 1.35 (0.91 to 2.00) .139
Smokers 96 0.52 1.52 (1.23 to 1.89) <.001 1.41 (1.13 to 1.77) .003
CI = confidence interval; NRT = nicotine replacement therapy; OR = odds ratio.
aAdjusted for maternal age, socioeconomic status, pre-pregnancy body mass index, and diabetes.
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United Kingdom, women are entitled to free NHS prescriptions dur-
ing pregnancy.43 Therefore, we believe that self-purchase of NRT 
would be infrequent in this group and misclassification in the expos-
ure measurement should be minimal; however, the true magnitude of 
exposure misclassification is potentially unquantifiable and therefore 
results should be interpreted with caution. Since 2010, in addition 
to its use for smoking cessation NRT has been indicated for harm 
reduction, such that smokers could use NRT to cut down on smok-
ing. Nevertheless, this indication does not apply to pregnant women. 
Therefore, we believe that simultaneous use of NRT and cigarettes 
should be minimal. Measuring concurrent usage in an epidemio-
logical study would only be possible with a detailed follow-up study 
that would need to have multiple prospective recordings of women’s 
smoking behavior and close behavior monitoring. Another potential 
concern is that prescriptions issued are not necessarily an indica-
tion of compliance to drug therapy, and some of the prescriptions 
issued may not have been redeemed. Similarly, smoking cessation 
does not necessarily follow being prescribed with NRT, and some 
women in receipt of prescriptions may have continued to smoke. 
However, a validation study comparing the recorded prescriptions 
for smoking cessation medications in THIN and the NHS dispensing 
data between January 2004 and December 2005 reported good com-
parability between the two data sources indicating that prescriptions 
recorded for smoking cessation medications in primary care data 
are collected by the patients.44 Furthermore, measuring actual drug 
consumption in any large population-based study is pragmatically 
difficult and is a limitation in previous studies as well.37
Accurate ascertainment of smoking status is also difficult, espe-
cially in pregnant women, due to the social stigma attached to smok-
ing. However, all previous epidemiological studies investigating the 
association between maternal smoking and stillbirth have similarly 
relied on self-reported smoking status data, as biochemical valid-
ation of large samples is expensive and often practically prohibitive 
throughout pregnancy. In our study, smoking status was self-reported 
in primary care and recorded during pregnancy by doctors, nurses, or 
midwives. Smoking prevalence from THIN based on the QOF rules, 
using information recorded within 27  months before pregnancy, 
shows good agreement with smoking estimates from other national 
datasets including the Scottish Morbidity Record and the Child 
Health Systems Programme data.17 Self-reports of smoking habit to 
health professionals invested in the person’s clinical care have shown 
to be reasonably accurate compared with those in bespoke studies.45
Interpretation in Light of Other Evidence
Our study found no statistically significant increased risk of still-
birth associated with NRT exposure during pregnancy. The study 
of 87 032 pregnancies from the DNBC had information on smok-
ing and NRT use that was self-reported by women during an inter-
view at approximately 17 weeks of gestation. For women who used 
NRT, there was no statistically significant increase in the risk of still-
birth (HR 0.57, 95% CI 0.28 to 1.16) compared with nonusers.46 
Furthermore, compared with nonsmokers and non-NRT users (ie, 
controls), the HR for stillbirth among women who smoked and used 
NRT simultaneously was 0.83 (95% CI 0.34 to 2.00) and among 
nonsmokers who used NRT was 0.67 (95% CI 0.21 to 2.08). 
However, the nonsmoker group in their study included ex-smokers 
who quit before conception but also women who were smoking dur-
ing pregnancy but not at the time of the interview, and therefore, it 
is quite difficult to exclusively differentiate between the two, which 
could potentially result in misclassification of the exposure. They 
also did not have information on smoking or NRT after the inter-
view so this is also a potential source of exposure misclassification. 
Furthermore, the time periods to define stillbirth were considerably 
different between both the DNBC study and our study: the DNBC 
study classified stillbirth as any fetus that did not breathe or show 
any other sign of life at birth after a minimum of 20 weeks of ges-
tation compared with 28 weeks in our study. The potential differ-
ences between the exposure window and definition of stillbirth and 
the small number of stillbirth cases in the NRT group (n  =  8) in 
the DNBC study could potentially explain the difference in findings. 
Nevertheless, our results are also in line with the pooled estimates 
from a meta-analysis of randomized controlled trial data (risk ratio 
1.24, 95% CI 0.54 to 2.84),10 again suggesting that the use of NRT 
does not significantly increase or reduce the risk of stillbirth.
While the effect estimates for NRT and smoking were very 
similar, we found a 41% statistically significant increase in the risk 
of stillbirth in smokers. Exposure misclassification or residual con-
founding could be potential explanations or it could be that nicotine 
whether in the form of NRT or cigarette has a very similar effect on 
the growing fetus. Nevertheless, the statistically significant associ-
ation between smoking and stillbirth is consistent with the current 
literature. The DNBC study found the risk of stillbirth to be 46% 
higher in smokers (HR 1.46, 95% CI 1.17 to 1.82) compared with 
nonsmokers using smoking information from the first trimester.46 
Similarly, another Danish study based on a cohort of 25 102 live 
born singleton children collected smoking data before 30 weeks of 
gestation and found the risk of stillbirth to be twice as high com-
pared with nonsmokers.47 Other studies that assessed smoking at 
the end of pregnancy or where the exact time of smoking assessment 
was not specified found the risk of stillbirth in smokers to be between 
34%48 and over twofold1,24,47,49,50 higher compared with nonsmokers.
Tobacco smoke contains many harmful chemicals including nico-
tine, carbon monoxide, and nitrogen oxides51,52 and reduces fetal 
oxygenation through increased blood levels of carboxyhaemoglobin 
and impairment of oxygen unloading.47 This, along with prostacyc-
lin synthesis, increases vascular resistance and decreases fetal blood 
flow. All these effects combined with the postulated vasoconstriction 
through nicotine47 could collectively result in fetal growth restriction 
and placental complications, which are the most important causes of 
stillbirth.53,54 However, we found the effect estimates in the NRT and 
smoking group to be very similar and compared directly to maternal 
smoking the risk estimates for stillbirth were not higher in the NRT 
group. Another potential explanation for the similar effect estimates 
in both groups is that pregnant women in the sample may have used 
only short courses of NRT (~2 weeks); long-term adherence with 
NRT in pregnancy has been poor in other studies. Data from the 
Smoking, Nicotine, and Pregnancy trial also show that only 7.2% 
women in the NRT group and 2.8% in the placebo group contin-
ued to use NRT beyond 1 month.11 Therefore, although we ensured 
that women prescribed NRT had no subsequent records of smoking 
throughout pregnancy, it is possible that some women did recom-
mence smoking but did not report it to their GP or midwife.
Conclusion
Previous evidence on maternal NRT exposure during pregnancy 
and the risk of stillbirth is limited and inconclusive. In this study, 
with much larger numbers than others, we did not find a protect-
ive or harmful effect of NRT prescribed during pregnancy as part 
of routine clinical care, in relation to stillbirth. While there may 
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be no true association between NRT exposure during pregnancy 
and stillbirth, the potential impacts of residual confounding, mis-
classification of the exposure, and limited power must be recog-
nized. An even larger study with biochemically validated data on 
active and passive smoking exposures, including close monitor-
ing of independent NRT use and concurrent use with smoking 
throughout the 9  months of pregnancy, is required to determine 
this more definitively. All data are anonymised, such that individual 
patients as well as the name and specific location of general prac-
tices cannot be identified by researchers. Ethical approval for this 
research was obtained from the South-East Multicentre Research 
Ethics Committee (SE-REC), reference 04/MRE01/9. All data are 
anonymised, such that individual patients as well as the name 
and specific location of general practices cannot be identified by 
researchers. Ethical approval for this research was obtained from 
the South-East Multicentre Research Ethics Committee (SE-REC), 
reference 04/MRE01/9.
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